A patient with acquired haemophilia A and pemphigus

Netherlands Journal of Medicine

Volumn 52, Issue 5, 1998, Pages 190-192

  Halbertsma, F J J ^a   Van Der Linden, P W G ^a   Mauser Bunschoten, E P ^b  

^a Department of Orthopaedic Surgery   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acquired hemophilia A; Pemphigus

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CORTICOSTEROID;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; HEMATOMA; HEMOPHILIA A; HUMAN; LABORATORY TEST; MALE; ORAL DRUG ADMINISTRATION; PEMPHIGUS;

AGED; FACTOR VIII; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEMATOMA; HEMOPHILIA A; HUMANS; LEG; MALE; PEMPHIGUS; PREDNISONE;

EID: 0032079099     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(98)00024-2     Document Type: Article

References (19)

1. [1] Schwarziger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate haemophilia A treated with F VIII concentrates. Am J Hematol 1987;24:241-245.
2. [2] Ehrenforth S, Kreuz W, Schrarrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of factor VIII and IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
3. [3] Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol 1981;48:635-642.
4. [4] Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81:1513-1520.
5. [5] Morrison AE. Acquired hemophilia and its management. Br J Haematol 1995;89:231-236.
6. [6] Green D. Cytotoxic suppression of acquired factor VIII:C inhibitors. Am J Med 1991;91(Suppl 5A):14-19.
7. [7] Nilsson IM, Berntdorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988;318:947-950.
8. [8] Kasper CK. Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989;9:57-86.
9. [9] Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to F VIII. Thromb Haemost 1981;45(3):200-203.
10. [10] Hultin MB. Acquired inhibitors in malignant and non-malignant disease states. Am J Med 1991;91(Suppl 5A):9-13.
11. [11] Benthaus J, Richter WC. Zum Krankheitsbild der Hemmkoerperhaemophilie. Dtsch Arch Klin Med 1956;203:1-9.
12. [12] Fischer M, Lechner K, Raith W. Hemmkorperhaemophilie bei bulloesen Pemphigoid (Lever). Hautarzt 1968;19:459-462.
13. [13] Dieter DG, Spooner M, Pohle FJ. Studies on an undetermined circulating anticoagulant. Case report and laboratory findings. Blood 1949;4:120-129.
14. [14] Shulman NR, Hirschman RJ. Acquired hemophilia. Trans Assoc Am Physiol 1969;82:388-397.
15. [15] Shapiro SS. The immunologic character of acquired inhibitors of antihemophiliac globulin (factor VIII) and the kinetics of their interaction with factor VIII. J Clin Invest 1967;46:147-156.
16. [16] Castaldi PA, Penny R. A macroglobulin with inhibitory activity against coagulation factor VIII. Blood 1970;34:370-376.
17. [17] Lubin IM, Healy JF, Scandella D, Runge MS, Lollar P. Elimination of a major inhibitor epitope in factor F VIII. J Biol Chem 1994;12:8639-8641.
18. [18] Kasper LM, Aledorf RB, Counts RB. More uniform measurement of F VIII inhibitors. Thromb Diath Hemorrh 1975;43:869-872.
19. [19] Hay CRM, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa. Haemophilia 1996;2:157.